Agreed. If you don’t believe in the management of PDMI, there’s no reason to be long here. That means trusting management when they put in the mechanisms that will guarantee PDMI’s survival during this vulnerable period. Sure 14 billion shares is a big number, but doesn’t it make PDMI a less tempting target for hostile takeover?
In the shorter term, this is an FDA play for Paramax/Retimax distribution in the USA. But in the longer term, this is a company turnaround play. This is about whether Stephen Davis can clean up the previous management’s mess, and bring out the company’s potential.
Demographics could favor long term holders. The population bulge formed by Baby Boomers in the US is reaching the age where glaucoma becomes a concern. The domestic market for ophthalmic treatments in general, and glaucoma treatments in particular, will only grow over the next ten years.
News 
Market Data 
Discover 
